TABLE 1.

Experimental design and efficacy parameters

Study and group	Vaccinationa		M. bovis challengeb			Pathology score (mean ± SEM)c	Culture (log CFU/g) (mean ± SEM)d
	Age (wk)	Interval (mo)	Strain	Dose (CFU)	Interval (mo)
Comparative virulence studye
No infection (n = 7)	NAf		NA	NA	NA	0 ± 0	0 ± 0
M. bovis strain 95-1315 infection (n = 8)	NA		95-1315	104	4	16.4 ± 2.5g	3.25 ± 0.33g
M. bovis strain 10-7428 infection (n = 8)	NA		10-7428	104	4	20.5 ± 1.3g	3.53 ± 0.20g
Vaccine efficacy study from 2014
No vaccination (n = 10)	NA		10-7428	600	4.5	12.0 ± 1.6	3.86 ± 0.28
BCG vaccination (n = 9)	3	3.5	10-7428	600	4.5	0.6 ± 0.4g	0.34 ± 0.34g
BCG mutant vaccination (n = 10)	3	3.5	10-7428	600	4.5	0.9 ± 0.4g	1.74 ± 0.72g
Vaccine efficacy study from 2007h
No vaccination (n = 11)	NA		95-1315	103	4.5	14.1 ± 1.4	3.95 ± 0.13
BCG vaccination (n = 11)	2	3	95-1315	103	4.5	3.4 ± 0.9g	2.59 ± 0.42g
M. bovis ΔRD1 vaccination (n = 10)	2	3	95-1315	103	4.5	6.0 ± 1.8g	2.62 ± 0.59g
RNA-Seq studyi
M. bovis strain 95-1315 infection (n = 6)	NA		95-1315	8 × 103	11	All had lesions	All were culture positive

^aAge of vaccination and interval between vaccination and aerosol challenge with virulent M. bovis.

^bStrain and dose of virulent strain administered by aerosol and interval between challenge and necropsy.

^cTotal gross pathology scores, which include scores for tracheobronchial and mediastinal (i.e., pulmonary) lymph nodes and lung lobes.

^dM. bovis CFU per gram of tracheobronchial lymph node.

^eSee reference 37 for additional details of this study.

^fNA, not applicable (i.e., animals were not vaccinated or challenged).

^gDiffers from the noninfected or nonvaccinated group within each study (P < 0.05, ANOVA followed by Tukey's multiple-comparison test).

^hSee reference 20 for additional details of this study.

ⁱPathology scoring and quantitative culture were not applied; however, all animals had tuberculous lesions and M. bovis was isolated from each animal.